Compound preparation for treating cardiovascular and cerebrovascular diseases

A technology for cardiovascular and cerebrovascular diseases and compound preparations, which is applied in the fields of cardiovascular system diseases, metabolic diseases, and pharmaceutical formulations. compliance effect

Inactive Publication Date: 2013-08-14
LIAONING YILING KECHUANG BIOLOGICAL MEDICAL TECH +1
View PDF1 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] Due to differences in age, course of disease, awareness of the disease, etc., hypertensive patients are seldom able to insist on taking one or more antihypertensive drugs and blood lipid lowering drugs, and the medica

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound preparation for treating cardiovascular and cerebrovascular diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Example 1: Ezetimibe Compound Capsules

[0043] (1000 formula quantity)

[0044] Element Weight (g) Function Simvastatin 10.53 active ingredient Ezetimibe 10.42 active ingredient Butylated Hydroxyanisole (BHA) 0.02 antioxidant microcrystalline cellulose 26.90 fillers, binders lactose 35.47 filler Crospovidone 2.54 disintegrant Hydroxypropylmethylcellulose 3.56 Adhesive Magnesium stearate 3.78 lubricants, glidants Amlodipine 5.27 active ingredient Sodium carboxymethyl starch 1.51 disintegrant Ethanol (85%) Appropriate amount Granulating liquid

[0045] The preparation process is:

[0046] (1) Sustained-release granules:

[0047] Mix 0.02g BHA, 10.53g simvastatin, and 10.42g ezetimibe with the same amount of microcrystalline cellulose, pass through an 80-mesh sieve and mix the above drugs again; Lipovidone, 1.56g of hydroxypropyl methylcellulose and 15g of lactose w...

Embodiment 2

[0053] Example 2: Ezetimibe compound double-layer tablet

[0054] (1000 formulation quantity)

[0055] Element Weight (g) Function Simvastatin 20.12 active ingredient Ezetimibe 9.58 active ingredient Butylated Hydroxyanisole (BHA) 0.02 antioxidant starch 2.36 fillers, disintegrants lactose 25.17 filler Mannitol 13.11 filler Polyvinylpyrrolidone (PVP) 0.33 Adhesive Ethyl cellulose 25.24 Adhesive Low-substituted hydroxypropyl cellulose 5.09 disintegrant Micropowder silica gel 3.75 lubricants, glidants Amlodipine 5.03 active ingredient Croscarmellose Sodium 0.56 disintegrant Ethanol (30%) Appropriate amount Granulating liquid

[0056] Preparation Process:

[0057] (1) Sustained-release tablet core: mix 9.58g ezetimibe with 2.36g starch and 13.11g mannitol, and then grind; mix 0.02g BHA and 5g lactose, and add 20.12g simvastatin; Mix the above medicines again,...

experiment example 3

[0065] Experimental example 3 Animal effectiveness experiment

[0066] In the experiment, Wistar male rats with body weight of 180-200g and blood pressure in the range of 85-155mmHg were used as normal control rats or model-making rats. The rats were fed with regular solid feed, and the experiment started after one week of acclimatization. The experimental rats used the improved method of "two kidneys and one clip" renal hypertension model combined with high-sugar and high-fat diet to prepare the hypertension compound hyperlipidemia model. A 0.25mm acupuncture needle was placed close to and parallel to the renal artery, ligated with sterile silk, and then pulled out, resulting in unilateral renal artery stenosis. Intraperitoneal injection of penicillin within 3 days after operation to prevent infection. After the function of the rats returned to normal, they were fed with standard feed and fat emulsion by gavage for 4 weeks, and the non-fasting blood pressure, triglyceride a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a compound preparation for treating cardiovascular and cerebrovascular diseases. The compound preparation comprises a cholesterol reuptake inhibitor, an HMG-CoA (3-hydroxy-3-methyl-glutaryl) reductase inhibitor and a calcium ion antagonist, and has the effect of jointly lowering blood pressure and lipid. According to the compound preparation, isolating layers or/and coatings are arranged for active ingredients or a part of active ingredients, and the usage amount of antioxidants in a precipitation is reduced, therefore, the medicine therapeutic range is expanded, the stability and safety of the medicine are improved; simultaneously, the medication compliance of a patient suffering from hypertension and hyperlipemia is improved.

Description

technical field [0001] The present invention relates to a compound preparation for treating cardiovascular and cerebrovascular diseases, in particular to a compound preparation containing cholesterol absorption inhibitor, 3-hydroxy-3 methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor and calcium ion antagonist A compound preparation for lowering blood pressure and lipid. Background technique [0002] Cardiovascular and cerebrovascular diseases are the main factors that threaten human life in the 21st century, and the death of cardiovascular and cerebrovascular diseases accounts for 40.8% of the deaths from chronic diseases in my country. Cardiovascular and cerebrovascular diseases are essentially vascular diseases. [0003] Hypertension is one of the most common cardiovascular diseases that endanger human health. In recent years, with the improvement of living standards, the prevalence of hypertension in my country has shown an obvious upward trend, and has now become ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61P9/12A61P3/06A61K45/06A61P9/10A61P3/10
Inventor 关屹闫冬
Owner LIAONING YILING KECHUANG BIOLOGICAL MEDICAL TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap